Cargando…
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481124/ https://www.ncbi.nlm.nih.gov/pubmed/26036592 http://dx.doi.org/10.1186/s13075-015-0662-x |
_version_ | 1782378245985927168 |
---|---|
author | Migita, Kiyoshi Akeda, Yukihiro Akazawa, Manabu Tohma, Shigeto Hirano, Fuminori Ideguchi, Haruko Matsumura, Ryutaro Suematsu, Eiichi Miyamura, Tomoya Mori, Shunsuke Fukui, Takahiro Izumi, Yasumori Iwanaga, Nozomi Tsutani, Hiroshi Saisyo, Kouichirou Yamanaka, Takao Ohshima, Shiro Sugiyama, Takao Kawabe, Yojiro Katayama, Masao Suenaga, Yasuo Okamoto, Akira Ohshima, Hisaji Okada, Yasumasa Ichikawa, Kenji Yoshizawa, Shigeru Kawakami, Kenji Matsui, Toshihiro Furukawa, Hiroshi Oishi, Kazunori |
author_facet | Migita, Kiyoshi Akeda, Yukihiro Akazawa, Manabu Tohma, Shigeto Hirano, Fuminori Ideguchi, Haruko Matsumura, Ryutaro Suematsu, Eiichi Miyamura, Tomoya Mori, Shunsuke Fukui, Takahiro Izumi, Yasumori Iwanaga, Nozomi Tsutani, Hiroshi Saisyo, Kouichirou Yamanaka, Takao Ohshima, Shiro Sugiyama, Takao Kawabe, Yojiro Katayama, Masao Suenaga, Yasuo Okamoto, Akira Ohshima, Hisaji Okada, Yasumasa Ichikawa, Kenji Yoshizawa, Shigeru Kawakami, Kenji Matsui, Toshihiro Furukawa, Hiroshi Oishi, Kazunori |
author_sort | Migita, Kiyoshi |
collection | PubMed |
description | INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS: IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0662-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4481124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44811242015-06-27 Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus Migita, Kiyoshi Akeda, Yukihiro Akazawa, Manabu Tohma, Shigeto Hirano, Fuminori Ideguchi, Haruko Matsumura, Ryutaro Suematsu, Eiichi Miyamura, Tomoya Mori, Shunsuke Fukui, Takahiro Izumi, Yasumori Iwanaga, Nozomi Tsutani, Hiroshi Saisyo, Kouichirou Yamanaka, Takao Ohshima, Shiro Sugiyama, Takao Kawabe, Yojiro Katayama, Masao Suenaga, Yasuo Okamoto, Akira Ohshima, Hisaji Okada, Yasumasa Ichikawa, Kenji Yoshizawa, Shigeru Kawakami, Kenji Matsui, Toshihiro Furukawa, Hiroshi Oishi, Kazunori Arthritis Res Ther Research Article INTRODUCTION: In rheumatoid arthritis (RA) patients receiving immunosuppressive treatments, vaccination against Streptococcus pneumoniae is recommended. The objective of the study was to evaluate the effects of tacrolimus (TAC) on immune response following administration of a 23-valent pneumococcal polysaccharide vaccine (PPSV23) in patients with established RA. METHODS: Patients with RA (n = 133) were vaccinated with PPSV23. Patients were classified into TAC (n = 29), methotrexate (MTX) (n = 55), control (n = 35), and TAC/MTX (n = 14) treatment groups. We measured the concentrations of pneumococcal serotypes 6B and 23F by using an enzyme-linked immunosorbent assay and determined antibody functionality by using a multiplexed opsonophagocytic killing assay, reported as the opsonization index (OI), before and 4 to 6 weeks after vaccination. A positive antibody response was defined as at least a twofold increase in the IgG concentration or as at least a 10-fold increase in the OI. RESULTS: IgG concentrations and OIs were significantly increased in all treatment groups after PPSV23 vaccination. The TAC treatment group appears to respond in a manner similar to that of the RA control group in terms of 6B and 23F serotype concentration and function. In contrast, the MTX group had the lowest immune response. Patients who received a combination of TAC and MTX (TAC/MTX) also had a diminished immune response compared with those who received TAC alone. CONCLUSIONS: TAC monotherapy does not appear to impair PPSV23 immunogenicity in patients with RA, whereas antibody production and function may be reduced when TAC is used with MTX. Thus, PPSV23 administration during ongoing TAC treatment should be encouraged for infection-prone TAC-treated patients with rheumatic diseases. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry: UMIN000009566. Registered 12 December 2012. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0662-x) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-03 2015 /pmc/articles/PMC4481124/ /pubmed/26036592 http://dx.doi.org/10.1186/s13075-015-0662-x Text en © Migita et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Migita, Kiyoshi Akeda, Yukihiro Akazawa, Manabu Tohma, Shigeto Hirano, Fuminori Ideguchi, Haruko Matsumura, Ryutaro Suematsu, Eiichi Miyamura, Tomoya Mori, Shunsuke Fukui, Takahiro Izumi, Yasumori Iwanaga, Nozomi Tsutani, Hiroshi Saisyo, Kouichirou Yamanaka, Takao Ohshima, Shiro Sugiyama, Takao Kawabe, Yojiro Katayama, Masao Suenaga, Yasuo Okamoto, Akira Ohshima, Hisaji Okada, Yasumasa Ichikawa, Kenji Yoshizawa, Shigeru Kawakami, Kenji Matsui, Toshihiro Furukawa, Hiroshi Oishi, Kazunori Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title_full | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title_fullStr | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title_full_unstemmed | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title_short | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
title_sort | pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481124/ https://www.ncbi.nlm.nih.gov/pubmed/26036592 http://dx.doi.org/10.1186/s13075-015-0662-x |
work_keys_str_mv | AT migitakiyoshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT akedayukihiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT akazawamanabu pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT tohmashigeto pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT hiranofuminori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT ideguchiharuko pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT matsumuraryutaro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT suematsueiichi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT miyamuratomoya pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT morishunsuke pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT fukuitakahiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT izumiyasumori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT iwanaganozomi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT tsutanihiroshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT saisyokouichirou pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT yamanakatakao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT ohshimashiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT sugiyamatakao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT kawabeyojiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT katayamamasao pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT suenagayasuo pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT okamotoakira pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT ohshimahisaji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT okadayasumasa pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT ichikawakenji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT yoshizawashigeru pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT kawakamikenji pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT matsuitoshihiro pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT furukawahiroshi pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus AT oishikazunori pneumococcalpolysaccharidevaccinationinrheumatoidarthritispatientsreceivingtacrolimus |